PR Newswire PharmaOriginal article
Cadence Neuroscience Receives FDA IDE Approval to Begin Multicenter Study of its Biomarker Targeted Stimulation Therapy for Focal Drug-Resistant Epilepsy
RegulatoryapprovedBiomarker Targeted Stimulation Therapy (BTSEE)Positive
AI Analysis
Summary
Cadence Neuroscience received FDA IDE approval to begin a multicenter prospective study of its biomarker targeted stimulation therapy for focal drug-resistant epilepsy. The study will enroll 45 pediatric and adult patients at up to 10 U.S. comprehensive epilepsy centers.
Clinical Trial Data
Patients
45
Outcome Details
FDA granted IDE approval to begin a multicenter prospective study (BTSEE) of biomarker targeted stimulation therapy in focal drug-resistant epilepsy.
Importance:5/10
Sentiment:
0.50
FDAIDE approvalepilepsyneurostimulationmedical devicepediatricmulticenter study
Read the original article
Published by PR Newswire Pharma on October 14, 2026 1:00 PM